Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMCR vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

IMCR Overall Winner 6-Pillar Tally: IMCR 5 – 1 ZBIO Matrix Metrics: IMCR 5 – 4 ZBIO

As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMCR carries a Unified Composite Score of 46.3/100 (HOLD) at $28.88 (22.6x Forward P/E, -2.2% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMCR vs ZBIO
IMCR NASDAQ Head-to-Head Winner
Immunocore Holdings plc American Depositary Shares
Biological Products, (No Disgnostic Substances)
$28.88
-3.54% 1D
Market Cap $1.5B
TTM Revenue $429M
Forward P/E 22.6x
Beta / 30D Vol 0.63β · 59% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 46.0 Fund 50.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.2%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $30.96 · SMA50: $30.93
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (IMCR 5 – 1 ZBIO)

Columns: Metric · IMCR · ZBIO
1. Valuation Multiples IMCR
Forward P/E 22.6x N/M
Trailing P/E 23.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.6x N/M
2. Growth & Scale IMCR
Revenue Growth (YoY) -1.4% -100.0%
Earnings Growth (YoY) +150.0% +0.0%
TTM Revenue (USD) $429M $11M
Market Cap $1.5B $1.9B
3. Profitability & Quality IMCR
Gross Margin 34.5% N/A
Operating Margin -2.2% -2747.5%
Net Profit Margin -7.5% 0.0%
Return on Equity (ROE) -7.9% -265.1%
4. Balance Sheet & Cash Flow IMCR
Cash Generation (TTM) -$5.4M EBITDA -$273M
Cash Flow Margin -1.3% EBITDA Mgn N/A
Net Cash / Leverage $8.13 Book/Sh · -7.9% ROE $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 56.7% (10th %ile) 103.9% (13th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat IMCR
OpEx & R&D Intensity 36.7% of Rev ($158M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMCR (5) vs ZBIO (4)
Institutional Metric IMCR ZBIO Criterion Row Edge
Market Capitalization
Scale
$1.5B $1.9B Larger Scale ZBIO
Trailing P/E Ratio
Valuation
23.8x N/M Lower Multiple IMCR
Forward P/E Ratio
Valuation
22.6x N/M Lower Multiple IMCR
Revenue Growth (YoY)
Growth
-1.4% -100.0% Higher Growth IMCR
Operating Margin (TTM)
Profitability
-2.2% -2747.5% Higher Margin IMCR
Net Profit Margin
Profitability
-7.5% 0.0% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
-7.9% -265.1% Higher ROE IMCR
52-Week Range Position
Momentum
10% ($28–$41) 46% ($14–$45) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
0.63β · 59% Vol 1.16β · 59% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$429M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.4M EBITDA ($8.13 Book/Sh · -7.9% ROE) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +14.21 pp
IMCR: -1.77% · ZBIO: +12.44%
3M Horizon ZBIO +7.35 pp
IMCR: -19.82% · ZBIO: -12.47%
6M Horizon ZBIO +63.37 pp
IMCR: +1.8% · ZBIO: +65.17%
1Y Horizon IMCR +3.33 pp
IMCR: -18.35% · ZBIO: -21.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMCR vs ZBIO. Trailing 12-month operating profitability (IMCR -2.2% vs ZBIO -2747.5%) and valuation multiples (IMCR 22.6x vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$429M
Gross Margin34.5%
Op. Margin-2.2%
ROE / Fwd P/E-7.9% · 22.6x
ZBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-2747.5%
ROE / Fwd P/E-265.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.7%
IV Percentile 10th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -2.2% operating margin.
OpEx & R&D Reinvestment 36.7% of Rev ($158M)
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMCR vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Immunocore Holdings plc (IMCR) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMCR carries a Unified Composite Score of 46.3/100 (HOLD) at $28.88 (22.6x Forward P/E, -2.2% operating margin), whereas ZBIO carries 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. IMCR 46.3/100 HOLD), IMCR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.2% vs. -2747.5% operating margin) and revenue trajectory (-1.4% vs. -100.0% YoY). Technical & Structure Timing Caution: IMCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMCR leads the Growth & Scale pillar: IMCR posts -1.4% YoY revenue growth and +150.0% YoY earnings growth on $429M TTM revenue (34.5% gross margin, -2.2% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). On trailing 12-month operating scale, IMCR generates $429M in USD-normalized revenue versus $11M for ZBIO. In operating R&D and SG&A reinvestment, IMCR deploys 36.7% of Rev ($158M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

IMCR screens cheaper on headline valuation multiples. IMCR trades at 22.6x Forward P/E, 23.8x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (-1.3% EBITDA margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMCR (-7.9% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, IMCR carries 56.7% implied volatility (10th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.63β · 59% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.